The authors discuss the biological understanding of tumor-infiltrating lymphocytes (TILs), their analytical and clinical validity and efforts towards the clinical utility in breast cancer, and the current status of programmed death-ligand 1and TIL testing across different continents.
[npj Breast Cancer]
Sorry, but the selected Zotpress account can't be found.
